MTOR and neoplasm: Not only does the dual mTOR/PI3K inhibitor NVP-BEZ235 exert potent anti-tumor activityin vivo but its effect can be further enhanced by the combination with inhibitors against other mitogenic pathways, such as the MEK/ERK inhibitors36,37.